Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 4/20 | 0.51 |
| ▸ | GSTM2 | P28161 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376331 | 0.81 | MEN1 (0.65) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL10646397 | 0.74 | KMT2A (0.35) | MEN1KMT2ACYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL27225074 | 0.73 | GSTP1 (0.54) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL16225668 | 0.73 | GSTP1 (0.54) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL29449334 | 0.73 | PDE7A (0.55) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL11409450 | 0.73 | GSTP1 (0.54) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL8563127 | 0.73 | MEN1 (0.59) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL28127 | 0.73 | PDE7A (0.55) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL17784719 | 0.72 | GSTP1 (0.53) | MEN1KMT2AGSTP1GSTM2CYP1A2 | |
| SCHEMBL15155567 | 0.72 | CYP3A4 (0.55) | MEN1KMT2AGSTP1GSTM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970239-B1 | SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9670190-B2 | Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2970239-A1 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159657-A1 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159657-A1 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275132-A1 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275132-A1 | PYRIDINYL AND PYRIMIDINYL SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR5, CX3CR1, CXCR3 | MEN1 4737/4885KMT2A 4630/4885GSTP1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.